BioCentury
ARTICLE | Company News

Gilead, Catamaran, Cigna Corp. sales and marketing update

February 9, 2015 8:00 AM UTC

Catamaran selected Gilead’s Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir as an exclusive therapy for HCV infections for both its national and value formularies and Cigna selected Harvoni as its preferred prescription to treat HCV genotype 1 infection. Harvoni is a fixed-dose combination of Sovaldi sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ledipasvir, an HCV NS5A protein. Catamaran declined to disclose pricing details. ...